Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Fell Below 20 DMA | Bearish | 2.30% | |
| Wide Bands | Range Expansion | 2.30% | |
| Shooting Star Candlestick | Bearish | -8.08% | |
| Doji - Bearish? | Reversal | -8.08% | |
| Wide Bands | Range Expansion | -8.08% | |
| Wide Bands | Range Expansion | -8.60% | |
| Up 3 Days in a Row | Strength | -8.60% |
| Alert | Time |
|---|---|
| Possible NR7 | about 20 hours ago |
| Possible Inside Day | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
| Up 3% | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.06 |
| 52 Week Low | 4.4 |
| Average Volume | 333,229 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 6.01 |
| 20-Day Moving Average | 5.12 |
| 10-Day Moving Average | 5.11 |
| Average True Range | 0.39 |
| RSI (14) | 40.48 |
| ADX | 15.88 |
| +DI | 22.62 |
| -DI | 24.67 |
| Chandelier Exit (Long, 3 ATRs) | 4.66 |
| Chandelier Exit (Short, 3 ATRs) | 5.58 |
| Upper Bollinger Bands | 5.87 |
| Lower Bollinger Band | 4.37 |
| Percent B (%b) | 0.35 |
| BandWidth | 29.33 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.25 |
| MACD Histogram | 0.0394 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.10 | ||||
| Resistance 3 (R3) | 5.09 | 5.02 | 5.07 | ||
| Resistance 2 (R2) | 5.02 | 4.96 | 5.02 | 5.05 | |
| Resistance 1 (R1) | 4.95 | 4.93 | 4.99 | 4.96 | 5.04 |
| Pivot Point | 4.88 | 4.88 | 4.89 | 4.88 | 4.88 |
| Support 1 (S1) | 4.81 | 4.82 | 4.85 | 4.82 | 4.74 |
| Support 2 (S2) | 4.74 | 4.79 | 4.74 | 4.73 | |
| Support 3 (S3) | 4.67 | 4.74 | 4.72 | ||
| Support 4 (S4) | 4.68 |
